title: Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
abstract: From April 1981 to February 2000, 105 patients with chronic myeloid leukemia (CML) underwent BMT from HLA-identical related donors at a single center. Eighty-eight patients were in chronic phase (CP), 11 patients in accelerated phase and six patients in blast crisis. Ten of these patients received a second BMT (BMT2). Comparison of BMT in CP with chemotherapy and/or alpha-IFN (n=70) was also made. Patients were given cyclophosphamide (CY) and single-dose TBI (CYTBI, n=38) or busulfan (BU) and CY (BUCY, n=67). Overall 54 patients are alive and 52 of them are disease-free with a median follow-up of 11.3 (range 1.1-19.4) years. Ten-year disease-free survival (DFS) in CP patients was better after BUCY, 61% (95% CI, 47-68%) than after CYTBI, 41% (95% CI, 23-61%) (P=0.07). For 88 patients who received a transplant in CP, results were significantly improved when BMT was performed within 1 year after diagnosis (P=0.02) or at an age < or = 25 years old (P=0.01). Ten-year survival in patients who received BMT in CP was better than in patients treated with chemotherapy (56% vs 10%; P=0.0001) or alpha-IFN-based treatment (33%; P=0.09) with survival curves crossing at 4.2 years and at 4 years, respectively. The probability of DFS after BMT2 was 60% (95% CI, 26-87%). CP patients who received BMT after CYTBI had a higher probability of relapse and transplant-related mortality than patients receiving BUCY (53% and 58% vs 9% and 34%; P=0.002 and P=0.08, respectively). All but six patients are currently on no medication and have resumed all activities without any limitation. These long-term results confirm that allogeneic BMT is the only curative approach for CML patients and should be offered to all patients with a suitable donor as soon after diagnosis as possible.
authors.affiliation: Unità Operativa di Ematologia e Centro Trapianti di Midollo Osseo di Muraglia, Azienda Ospedaliera S, Salvatore di Pesaro, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Gaziev
authors.forename: M
authors.initials: M
authors.lastname: Galimberti
authors.forename: P
authors.initials: P
authors.lastname: Polchi
authors.forename: E
authors.initials: E
authors.lastname: Angelucci
authors.forename: C
authors.initials: C
authors.lastname: Giardini
authors.forename: D
authors.initials: D
authors.lastname: Baronciani
authors.forename: M
authors.initials: M
authors.lastname: Andreani
authors.forename: B
authors.initials: B
authors.lastname: Persini
authors.forename: B
authors.initials: B
authors.lastname: Erer
authors.forename: P
authors.initials: P
authors.lastname: Sodani
authors.forename: M
authors.initials: M
authors.lastname: Manna
authors.forename: G
authors.initials: G
authors.lastname: Nicolini
authors.forename: G
authors.initials: G
authors.lastname: Visani
authors.forename: G
authors.initials: G
authors.lastname: Lucarelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000633:toxicity; D016026:Bone Marrow Transplantation / Q000379:methods* / Q000401:mortality / Q000592:standards; D002648:Child; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007372:Interferons / Q000008:administration & dosage* / Q000633:toxicity; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000139:chemically induced / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016019:Survival Analysis; D014184:Transplantation, Homologous / Q000379:methods / Q000401:mortality / Q000592:standards; D016896:Treatment Outcome
chemical_list: D007372:Interferons